VivoSeq
Other

Eye Infection

20

Pipeline Programs

0

Active Trials

9

Companies Involved

Eye Infection is an emerging landscape with 20 programs across 9 companies. The most active players are Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Bayer, Dexcel Pharma Technologies Ltd.. 18 therapies are approved with 1 more in late-stage development.

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

0/100

Mech. Concentration

31/100

Completion Rate

N/A

Attrition Rate

N/A

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)